Thermo Fisher Scientific Inc. (TMO) — closed signal from July 24, 2025
Target reached Published before the outcome was known, scored automatically when the window closed on October 22, 2025.
Predicted vs. what happened
What happened
Reached its target in 88 days.
The thesis — published July 24, 2025
The stock jumped 9.1% after earnings, with three times normal trading, and the company raised its 2025 goals. Core sales grew 3 points faster than expected, and a key supplier also sounded upbeat, showing demand is real. The shares are holding above about $450, and past moves like this often add another 18-22% within three months, which could lift the price toward $560.
Primary drivers
- Strong Q2 and higher 2025 goals hint that drug makers are spending again
- Big post-earnings jump on heavy trading may draw in fast-moving investors
- Another supplier raised its view, confirming demand for lab products
- Healthcare stocks often hold up when markets fall, adding balance
How it played out
TMO: target reached in 88 days
Lyra published TMO at $465.94 on 2025-07-24 with an 18% short-term expected gain and a $548.90 target. The thesis pointed to a 9.1% post-earnings jump, three times normal trading, higher 2025 goals, core sales running 3 points faster than expected, firmer lab-products demand, support near $450, and a defensive healthcare profile.
Inside the window, the stock reached $570.86 on 2025-10-22. That was above the target, with a 22.5% peak gain, and the target was reached in 88 days. It ended at $566.77. The thesis played out.
Prices are shown split- and dividend-adjusted, matching what public charts show today.
Share this receipt
A scored call, published before the outcome was known. Paste the link anywhere — it unfurls as the card above.
Read the next call before it closes.
This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.